% | $
Quotes you view appear here for quick access.

Coronado Biosciences, Inc. Message Board

  • chiragpatel75 chiragpatel75 Apr 8, 2013 11:17 AM Flag

    Very Quite Before Storm

    Very quite board today and volume is extremely low compared to average. Maybe we will see spike after tomorrow's event.
    Any idea how is phaseII trails are going on for Crohn's Disease?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • No news as this clinical trial will have an end in the summer at the best and for sure early in Autumn. It's a test of 3 months and CNDO has to analyse it thereafter so expect another 5-6 months. We should load up before the results because I am sure based on my DD that the results will be awesome.

      In the interim we will have the CC TOMORROW.

      I quote CNDO :

      "The phase 2 trial is a randomized, double-blind, placebo-controlled clinical study designed to examine the safety and efficacy of TSO treatment in active left-sided ulcerative colitis and its effects on mucosal immune state and microbiota. The trial will randomize 120 people in a 1:1 ratio to receive either TSO 7500 or placebo. Participants will receive six doses of TSO 7500 or placebo orally every other week over a 12-week treatment period. The trial will evaluate the effect of TSO on clinical response of UC, intestinal mucosal immunological response, and inflammatory markers. The primary endpoint will be the percentage of patients who achieve response (reduction of UCDAI of = 3) by Week 12. The trial is planned to begin during the first quarter of 2013.

      Stephen Hanauer, MD, the Principal Investigator of the study, is a Professor of Medicine and Clinical Pharmacology at the University of Chicago, where he is currently Chief of Gastroenterology, Hepatology and Nutrition and Director of The Logan Center for GI Clinical Research. Dr. Hanauer is a world leader in the treatment of inflammatory bowel diseases (IBD).

      “We are very excited to work with the NIH and Coronado to evaluate the potential of TSO as a treatment for ulcerative colitis,” stated Dr. Hanauer. “One of the exciting aspects of the Autoimmunity Centers of Excellence grants is the translational research component of the trial that should provide further insights into the mechanism of action of TSO with regards to genetics, the microbiome and the impact on chronic immune-mediated inflammation.”

      Sentiment: Strong Buy

4.110.0000(0.00%)Apr 23 3:59 PMEDT